Dietary Fiber Reduces Risk of Death Post-colorectal Cancer Diagnosis

Share this content:
For this prospective study, researchers evaluated dietary and mortality data from 1575 health care professionals with stage I to III CRC.
For this prospective study, researchers evaluated dietary and mortality data from 1575 health care professionals with stage I to III CRC.

Patients with non-metastatic colorectal cancer (CRC) may have improved CRC-specific and overall mortality through a daily fiber intake increase, according to a study published in JAMA Oncology.1

For this prospective study, researchers evaluated dietary and mortality data from 1575 health care professionals with stage I to III CRC.

Over a median 8 years of follow-up, there were 773 reported deaths, of which 174 (22.5%) were CRC-specific.

The results showed an inverse relationship between high dietary fiber–intake and CRC-specific mortality: the multivariable hazard ratio (HR) for each 5-gram daily fiber–intake increase for CRC-specific mortality was 0.78 (95% CI, 0.65-0.93; P = .006), and 0.86 (95% CI, 0.79-0.93; P < .001) for all-cause mortality.

Patients who increased their daily intake upon diagnosis had a lower mortality rate. Each 5-gram increase led to an 18% and 14% reduction in CRC-specific mortality (95% CI, 7%-28%; P = .002) and all-cause mortality (95% CI, 8%-19%; P < .001), respectively.

The source of dietary fiber was also a factor. Fiber from cereal decreased CRC-specific mortality and all-cause mortality; vegetable fiber was associated with a lower all-cause mortality but not with CRC-specific mortality; fruit fiber was not associated with a reduction in either outcome.

Reference

  1. Song M, Wu K, Meyerhardt JA, et al. Fiber intake and survival after colorectal cancer diagnosis. JAMA Oncol. 2017 Nov 2. doi: 10.1001/jamaoncol.2017.3684 [Epub ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters